$SAGE

Ovid Therapeutics Inc. reported its fourth quarter earnings for 2025, showcasing a substantial increase in revenue driven by higher demand for its neurological treatment product line. Cost management strategies implemented over the past year led to a lower operational expenditure, resulting in a narrower loss per share than anticipated. The company's pipeline continues to advance, with promising data from clinical trials suggesting potential for future growth. During the earnings call, management provided optimistic guidance for the upcoming quarters, anticipating further revenue climbs. Investor sentiment appears bullish as Ovid sees expanding market opportunities and a commitment to innovation in treatment solutions.